Despite the success of intravitreal anti-VEGF therapy in treating age-related macular degeneration, serious concerns abound over the potential burden of repeated injections. Although still in the early stages of development, candidate drug therapies could offer the theoretical potential of enhancing anti-VEGF efficacy and, perhaps, leading to...

A convergence of scientific and clinical observations and new technologies paved the way for a hallmark genetic discovery that changed the course of AMD research. Four articles published early in 2005 demonstrated an association between AMD and common variants (or polymorphisms) in the complement factor H gene (CFH) on human chromosome 1q31, a...

Potentia Pharmaceuticals has successfully completed a phase 1 clinical trial of a complement factor C3 inhibitor for treating age-related macular degeneration, the company announced in a press release. The open-label, multicenter ASaP (Assessment of safety of intravitreal POT-4 therapy for patients with neovascular age-related macular...

Potentia Pharmaceuticals, a biotechnology company announced that the Company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of...

Potentia Pharmaceuticals has completed a $12 million round of fundraising to help it move its potentially groundbreaking drug to fight macular degeneration through clinical trials. Founded in 2001 by Harvard-trained scientists, Potentia moved in 2003 to Louisville, where co-founder Cedric Francois had done research at U of L. Francois said...